Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: A risk factor

Human Immunology

Volumn 70, Issue 8, 2009, Pages 618-622

  Gupta, Arun ^a   Sinnott, Paul ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Clinical relevance; Kidney transplant; Pretransplant antibodies; Sensitization; Solid phase assays

Indexed keywords

ALLOANTIBODY; CD20 ANTIBODY; HLA ANTIBODY; IMMUNOGLOBULIN;

ANTIBODY DETECTION; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT SURVIVAL; HIGH RISK POPULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTOTOXICITY; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PLASMAPHERESIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SENSITIZATION; SURGICAL PATIENT;

ANTIBODY FORMATION; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GRAFT REJECTION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNIZATION; IMMUNOSORBENT TECHNIQUES; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MICROSPHERES; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; WAITING LISTS;

EID: 68049118561     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.04.020     Document Type: Article

References (64)

1. Dausset H. Leukoagglutinins. IV. Leukoagglutinins and blood transfusion. Vox Sang 4 (1954) 190
2. Friedman E.A., Retan J.E., and Marshall D.C. Accelerated skin graft rejection in humans preimmunized with homologous peripheral leukocytes. J Clin Invest 40 (1961) 2162-2170
3. Patel R., and Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280 (1969) 735-739
4. Terasaki P.I., and McClelland J.D. Microdroplet assay of human serum cytotoxins. Nature 204 (1964) 998-1000
5. UKT Report 2007-2008. http://www.UKtransplant.org
6. Fuggle S.V., and Martin S. Tools for human leukocyte antigen antibody detection and their application to transplant in sensitised patients. Transplantation 86 (2008) 384-390
7. Morales-Buenrostro L.E., Terasaki P.I., Mariono-Vazquez L.A., Lee J.H., El-Awar N., and Alberu J. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 86 (2008) 1111-1115
8. Mizutani K., Terasaki P., Rosen A., Esquenazi V., Miller J., Shih R.N., et al. Serial ten year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 5 (2005) 2265-2272
9. Girnita A.L., Girnita D.M., and Zeevi A. Role of anti-HLA antibodies in allograft rejection. Curr Opin Organ Transplant 12 (2007) 420-425
10. Martin S., and Taylor C.J. The immunologically sensitized renal transplant recipients: the impact of advances in technology on organ allocation and transplant outcome. Transplant Rev 13 (1999) 40
11. Feucht H.E., and Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int 50 (1996) 1464-1475
12. Worthington J.E., Langton A., Liggett H., Robson A.J., and Martin S. A novel strategy for the detection and definition of HLA-specific antibodies in patients awaiting renal transplantation. Transpl Intl 11 (1998) S372-S376
13. Gigsby S.J., D'Souza J.M., Banwart R.P., et al. A comparison of CDC and Luminex for the detection of HLA antibody. Hum Immunol 66 (2005) 88
14. Zachary A.A., Ratner L.E., Graziani J.A., Lucas D.F., Delaney N.L., and Leffell M.S. Characterisation of HLA class I specific antibodies by ELISA using solubilised antigen targets: II. Clinical relevance. Hum Immunol 62 (2001) 236-246
15. Kao K.J., Scornik J.C., and Small S.J. Enzyme-linked immunoassay for anti-HLA antibodies-An alternative to panel studies by lymphocytotoxicity. Transplantation 55 (1993) 192-196
16. Scornik J.C., Salomon D.R., Lim P.B., Howard R.J., and Pfaff W.W. Post transplant antidonor antibodies and graft rejection: evaluation by two-color flow-cytometry. Transplantation 47 (1989) 287
17. Al-Hussein K.A., Shenton B.K., Bell A., Talbot D., Clark K.R., Rigg K.M., et al. Characterisation of donor-directed antibody class in the post-transplant period using flow cytometry in renal transplantation. Transpl Int 7 (1994) 182-189
18. Halloran P.F., Schlaut J., Solex K., and Srinivasa N.S. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 53 (1992) 550-555
19. Monteiro F., Buelow R., Mineiro C., Rodrigues H., and Kalil J. Identification of patients at high risk of graft loss by pre- and post transplant monitoring of anti-HLA class I IgG antibodies by enzyme-linked immunosorbent assay. Transplantation 63 (1997) 542-546
20. Schonemann C., Groth J., Leverenz S., and May G. HLA class I and class II antibodies: monitoring before and after kidney transplantation and their clinical relevance. Transplantation 65 (1998) 1519-1523
21. Piazza A., Adorno D., Poggi E., Borrelli L., Buonomo O., Pisani F., et al. Flow cytometry crossmatch: a sensitive technique for assessment of acute rejection in renal transplantation. Transplant Proc 30 (1998) 1769-1771
22. Christiaans M.H., Overhof-de Roos R., Nieman F., van Hoof J.P., and van den Berg-Loonen E.M. Donor specific antibodies after transplantation by flow cytometry: relative change in fluorescence ratio most sensitive risk factor for graft survival. Transplantation 65 (1998) 427-433
23. Nickeleit V., and Mihatsch M. Kidney transplants, antibodies and rejection: is C4d a magic marker?. Nephrol Dial Transplant 18 (2003) 2232-2239
24. Abe M., Kawai T., Futatsuyama K., Tanabe K., Fuchinoue S., Teraoka S., et al. Postoperative production of anti-donor antibody and chronic rejection in renal transplantation. Transplantation 63 (1997) 1616-1619
25. Kerman R.H., Susskind B., Kerman D.H., Lam M., Gerolami K., Williams K., et al. Anti-HLA antibodies detected in post transplant renal allograft recipient sera correlate with chronic rejection. Transplant Proc 29 (1997) 1515-1516
26. Fahim T., Bohmig G.A., Exner N.H., Kerchner H., Kandutsch S., Kerjaschki A.B., et al. The cellular lesion of humoral rejection: Predominant recruitment of monocytes to monocytes to peritubular and glomerular capillaries. Am J Transplant 7 (2007) 385-393
27. Tang A., and Platt J. Accommodation of grafts: implications of health and disease. Hum Immunol 68 (2007) 645-651
28. Sun Q., Liu Z.H., Cheng Z., Chen J., Ji S., Zeng C., and Li S. Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil. Kidney Int 71 (2007) 24-30
29. Martin S., and Claas F. Antibodies and crossmatching for transplantation. In: Dyer P.A., and Middleton D. (Eds). Histocompatibility testing-a practical approach (1993), IRL Press, Oxford 91
30. Sinnott P.J., Kippax R.I., Sheldon S., and Dyer P.A. A simple and rapid method for the detection of lymphocytotoxic antibodies using cell panels frozen on Terasaki plates. Tissue Antigens 26 (1985) 318-322
31. Susal C., Pelzl S., Simon T., and Opelz G. Advances in pre- and post transplant immunologic testing in kidney transplantation. Transplant Proc 36 (2004) 29-34
32. Kerman R.H., Susskind B., Buelow R., Regan J., Pouletty P., Williams J., et al. Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection. Transplantation 62 (1996) 201-205
33. Vignali D.A. Multiplexed particle-based flow cytometric assays. J Immunol Methods 243 (2000) 243-255
34. Vaidya S., Partlow D., Susskind B., Noor M., Barnes T., and Gugliuzza K. Prediction of crossmatch outcome of highly sensitised patients by single and/or multiple antigen bead assay. Transplantation 82 (2006) 1524-1528
35. Higgins R., Hathaway M., and Lowe D. Blood levels of donor specific human leukocyte antigen antibodies after renal transplantation: resolution of rejection in the presence of circulating donor-specific antibody. Transplantation 84 (2007) 876-884
36. Zhang Q., Liang L.W., Gjertson D.W., Lassman C., Wilkinson A.H., Kendrick E., et al. Development of post transplant anti donor HLA antibodies is associated with acute humoral rejection and early graft dysfunction transplantation 79 (2005) 591-598
37. Fuller A.A., Trevithick J.E., Rodey G.E., Parham P., and Fuller T.C. Topographic map of the HLA-A2 CREG epitopes using human alloantibody probes. Hum Immunol 28 (1990) 284-305
38. El-Awar N.R., Akaza T., Terasaki P.I., and Nguyen A. Human leukocyte antigen class i epitopes: update to 103 total epitopes, including the C locus. Transplantation 84 (2007) 532-540
39. Smith J.D., Hamour I.M., Banner N.R., and Rose M.L. C4d fixing Luminex binding antibodies-a new tool for prediction of graft failure after heart transplantation. Am J Transplant 7 (2007) 1-7
40. Gebel H.M., Harris S.B., Zibari G., and Bray R. Conundrum with Flow PRA beads. Clin Transplant 16 (2002) 24-29
41. Saidman S.L. Histocompatibility testing for highly sensitised transplant candidates Transplant Proc 39 (2007) 673-675
42. Schwaartz A., Gaigalas A.K., Wang L., Marti G.E., Vogt R.F., and Fernandez-Repollet E. Formalization of the MESF unit of fluorescence intensity. Cytom B Clin Cytom 57 (2004) 1-6
43. Eckels D.D. Solid phase testing in the HLA laboratory: implications for organ allocation. Int J Immunogenet 35 (2008) 265
44. Claas F.H., De Meester J., Witvliet M.D., Smits J.M., Persijn G.G., and Doxiadis I.I. Acceptable HLA mismatches for highly immunized patients. Rev Immunogenet 1 (1999) 351
45. Gupta A., Iveson V.I., Varagunam M., Bodger S., Sinnott P., and Thuraisingham R. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?. Transplantation 85 (2008) 1200-1204
46. van den Berg-Loonen E.M., Billen E.V.A., Voorter C.E.M., van Heurn L.W.E., Class F.H.J., van Hooff J.P., et al. Clinical relevance of donor specific antibodies detected by singly antigen beads in highly sensitised renal transplant patients. Transplantation 85 (2008) 1086-1090
47. Lefaucheur C., Nochy D., Hill G.S., Suberbielle-Boissel C., Antoine C., Charron D., et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 7 (2007) 832-841
48. Karpinsky M., Rush D., Jeffrey J., Exner M., Regele H., Dancea S., et al. Flow-cytometry crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 12 (2001) 2807-2814
49. Thielke J.J., West-Thielke P.M., Herren H.L., Bareato U., Ommert T., Vidaovic V., et al. Living donor kidney transplantation across positive crossmatch: The University of Illinois at Chicago experience. Transplantation 87 (2009) 268-273
50. Lefaucheur C., Suberbielle-Boissel C., Hill G.S., Nochy D., Andrade J., Antoine C., et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Contrib Nephrol 162 (2009) 1-12
51. Stegall M.D., Gloor J., Winters J.L., Moore S.B., and Degoey S. A comparison of plasmapheresis versus high-dose IVIg desensitisation in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6 (2006) 346-351
52. Patel A.M., Pancoska C., Mulgaonkar S., and Weng F.L. Renal transplantation in patients with pre-transplant donor specific antibodies and negative flow cytometry crossmatches. Am J Transplant 7 (2007) 2371-2377
53. Wolf R.A., Ashby V.D., and Milford E.L. Comparison of mortality in all patients on dialysis: patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant. N Engl J Med 341 (1999) 1725-1730
54. Crew R.J., and Ratner L.E. Transplanting the sensitized patient. Curr Opin Organ Transplant 12 (2007) 415-419
55. Bingaman A.W., Murphey C.L., Palma-Vargas J., and Wright F. A virtual crossmatch protocol significantly increased access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 86 (2008) 1864-1868
56. Howard M.G., and Bray R.A. Laboratory assessment of HLA antibodies circa 2006: making sense of sensitivity. Transplant Rev 20 (2006) 189-194
57. Jordan S.C., Vo A., Bunnpradist S., Toyoda M., Peng A., Pullyanda D., et al. Intravenous immunoglobulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organ in living donor and cadaver recipients. Transplantation 76 (2003) 631-636
58. Zachary A.A., Montgomery R.A., and Leffell M.S. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 66 (2005) 364-370
59. Gloor J.M., Cosio F.G., Rea D.J., Wadel H.M., Winters J.L., Moore S.B., et al. Histologic findings one year after positive crossmatch or ABO incompatible living donor kidney transplantation. Am J Transplant 6 (2006) 1841-1847
60. Reinsmoen N.L., Lai C.H., Vo A., Cao K., Ong G., Naim M., et al. Acceptable donor specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 86 (2008) 820-825
61. Miztuani K., Terasaki P., Hamdani E., Esquenaazi V., Rosen A., Miller J., et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 7 (2007) 1027-1031
62. Haas M., Montgomery R.A., Segev D.L., Rahman M.H., Racusen L.C., Bagnasco S.M., et al. Subclinical acute antibody mediated rejection in positive renal allograft. Am J Transplant 7 (2007) 576-585
63. Cho Y.W., and Cecka J.M. Crossmatch tests-an analysis of UNOS data from 1991-2000. Clin Transplant (2001) 237-246
64. Rizzello A, Sinnott P, Gupta A, Thuraisingham R, Puliatti C, Cacciola R. Do we always need cross-match before proceeding to renal transplant? RA BTS Annual Conference 2009, p 386.